MENU
+Compare
BBIO
Stock ticker: NASDAQ
AS OF
Aug 7 closing price
Price
$45.95
Change
+$1.14 (+2.54%)
Capitalization
8.78B

BBIO BridgeBio Pharma Forecast, Technical & Fundamental Analysis

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases... Show more

BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BBIO with price predictions
Aug 07, 2025

Momentum Indicator for BBIO turns positive, indicating new upward trend

BBIO saw its Momentum Indicator move above the 0 level on August 07, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 173 cases where BBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BBIO moved out of overbought territory on August 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where BBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BBIO turned negative on July 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BBIO broke above its upper Bollinger Band on August 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (57.859). BBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.470). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (36.900) is also within normal values, averaging (276.117).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BBIO is expected to report earnings to fall 20.38% to -75 cents per share on October 30

BridgeBio Pharma BBIO Stock Earnings Reports
Q3'25
Est.
$-0.76
Q2'25
Missed
by $0.20
Q1'25
Beat
by $0.03
Q4'24
Missed
by $0.27
Q3'24
Beat
by $0.13
The last earnings report on August 05 showed earnings per share of -94 cents, missing the estimate of -75 cents. With 2.66M shares outstanding, the current market capitalization sits at 8.78B.
A.I. Advisor
published General Information

General Information

a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3160 Porter Drive
Phone
+1 650 391-9740
Employees
556
Web
https://www.bridgebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UOPIX130.44N/A
N/A
ProFunds UltraNASDAQ-100 Inv
GSLAX16.34N/A
N/A
Goldman Sachs Large Cap Value A
VVIAX69.05N/A
N/A
Vanguard Value Index Adm
ETMGX30.13N/A
N/A
Eaton Vance Tx-Mgd Small-Cap A
BDSIX18.31N/A
N/A
BlackRock Advantage Small Cap Core Instl

BBIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ROIV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
+2.54%
ROIV - BBIO
44%
Loosely correlated
-0.86%
AXON - BBIO
44%
Loosely correlated
+0.85%
IRON - BBIO
44%
Loosely correlated
-3.27%
ARRY - BBIO
43%
Loosely correlated
+1.92%
PMN - BBIO
43%
Loosely correlated
-6.76%
More